Anavex Life Sciences Corp. SEC filings AVXL
Anavex Life Sciences Corp. has 634 filings in SEC EDGAR's recent list, going back to Jan 13, 2005. Its latest annual report, Form 10-K, was filed on Nov 25, 2025 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 28, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (officer or director change). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Sep 15, 2026 | — |
| DEFA14A | Additional proxy material | Sep 14, 2026 | — |
| DEFA14A | Additional proxy material | Sep 8, 2026 | — |
| DEFA14A | Additional proxy material | Sep 4, 2026 | — |
| DEFA14A | Additional proxy material | Sep 1, 2026 | — |
| DEFA14A | Additional proxy material | Aug 31, 2026 | — |
| DEFA14A | Additional proxy material | Aug 24, 2026 | — |
| DEFA14A | Additional proxy material | Aug 17, 2026 | — |
| DEFA14A | Additional proxy material | Aug 17, 2026 | — |
| DEFA14A | Additional proxy material | Aug 11, 2026 | — |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | May 6, 2024 | — |
| DEF 14A | Proxy statement | May 6, 2024 | May 6, 2024 |
| DEFA14A | Additional proxy material | Apr 4, 2023 | — |
| DEF 14A | Proxy statement | Apr 4, 2023 | Apr 4, 2023 |
| DEFA14A | Additional proxy material | Apr 11, 2022 | — |
| DEF 14A | Proxy statement | Apr 11, 2022 | Apr 11, 2022 |
| DEF 14A | Proxy statement | Apr 12, 2021 | Apr 12, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 1, 2021 | Apr 1, 2021 |
| DEFA14A | Additional proxy material | Mar 23, 2020 | — |
| DEF 14A | Proxy statement | Feb 20, 2020 | Apr 7, 2020 |
| DEF 14A | Proxy statement | Feb 11, 2019 | Apr 5, 2019 |
| PRE 14A | Preliminary proxy statement | Jan 31, 2019 | Jan 29, 2019 |
| DEF 14A | Proxy statement | Mar 8, 2018 | Apr 17, 2018 |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEF 14A | Proxy statement | Mar 10, 2017 | Apr 18, 2017 |
| PRE 14A | Preliminary proxy statement | Feb 27, 2017 | Feb 27, 2017 |
| DEF 14A | Proxy statement | Apr 1, 2016 | May 6, 2016 |
| DEF 14A | Proxy statement | Feb 13, 2015 | Mar 26, 2015 |
| PRE 14A | Preliminary proxy statement | Jan 30, 2015 | Jan 29, 2015 |
| DEF 14A | Proxy statement | Mar 4, 2011 | Apr 11, 2011 |
| DEF 14A | Proxy statement | Apr 1, 2010 | Apr 28, 2010 |
| DEF 14A | Proxy statement | Feb 27, 2009 | Apr 8, 2009 |
| DEF 14A | Proxy statement | Mar 11, 2008 | Apr 1, 2008 |
| DEF 14A | Proxy statement | Apr 30, 2007 | Apr 25, 2007 |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AVXL (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer, Smaller reporting company
- SEC CIK
- 1314052
- Former names
- Thrifty Printing Inc. (until Jan 25, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.